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Abstract
Background: Anticoagulation using vitamin K antagonists (VKAs) significantly reduces the risk of recurrent stroke in
stroke patients with atrial fibrillation (AF) and is recommended by guidelines.
Methods: The German Competence NETwork on Atrial Fibrillation established a nationwide prospective registry
including 9,574 AF patients, providing the opportunity to analyse AF management according to German healthcare
providers.
Results: On enrolment, 896 (9.4 %) patients reported a prior ischaemic stroke or transient ischaemic attack. Stroke
patients were significantly older, more likely to be female, had a higher rate of cardiovascular risk factors, and more
frequently received anticoagulation (almost exclusively VKA) than patients without prior stroke history. Following
enrolment, 76.4 % of all stroke patients without VKA contraindications received anticoagulation, which inversely
associated with age (OR 0.95 per year; 95 % CI 0.92–0.97). General practitioners/internists (OR 0.40; 95 % CI 0.21–0.77) and
physicians working in regional hospitals (OR 0.47; 95 % CI 0.29–0.77) prescribed anticoagulation for secondary stroke
prevention less frequently than physicians working at university hospitals (reference) and office-based cardiologists
(OR 1.40; 95 % CI 0.76–2.60). The impact of the treating healthcare provider was less evident in registry patients without
prior stroke.
Conclusions: In the AFNET registry, anticoagulation for secondary stroke prevention was prescribed in roughly
three-quarters of AF patients, a significantly higher rate than in primary prevention. We identified two factors associated
with withholding oral anticoagulation in stroke survivors, namely higher age and—most prominently—treatment by a
general practitioner/internist or physicians working at regional hospitals.
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Background
Atrial fibrillation (AF) is the most frequent clinically
relevant arrhythmia worldwide and affects 1–2 % of the
population. As it predominantly affects the elderly, AF
prevalence is expected to increase as the population ages
and the number of predisposing conditions increases [1, 2].
AF is independently associated with a threefold risk of
heart failure, higher all-cause mortality, and a four to five-
fold higher risk of ischaemic stroke. AF-associated strokes
tend to be more disabling and life-threatening than non-
cardio-embolic strokes [1, 3]. Notably, stroke risk is
independent of AF pattern (paroxysmal, persistent, per-
manent) [4] but correlates with coexisting cardiovascular
risk factors, especially prior ischaemic stroke and old age
[1, 5]. AF-related stroke risk can be significantly reduced
by oral anticoagulation, as stated in recent guidelines [1, 6].
However, infear of both bleeding complications and mul-
tiple drug interactions, VKAs are underused in routine
clinical practice specifically, underuse has been reported
in elderly AF patients, those with a prior history of stroke,
paroxysmal AF, minor falls, dementia, and patients treated
by a general practitioner [7–12].
The publicly-funded German Competence NETwork
on Atrial Fibrillation (AFNET) established a nationwide
registry with 9,574 AF patients [12]. Patients were re-
cruited by general practitioners, internists, and cardiolo-
gists who were office-based, affiliated with specialized
referral centres, or part of a community or teaching
hospital. Therefore, this registry provides an exclusive
opportunity to analyse clinical AF management across
various healthcare levels in Germany [12].
The aims of this analysis were: (I) to characterise car-
diovascular risk and antithrombotic medication profiles
of AF patients with prior ischaemic stroke before enrol-
ment to the AFNET registry; (II) to determine factors
associated with withholding oral anticoagulation in
stroke survivors with AF, including the potential impact
of the type of the treating healthcare provider.
Methods
The design of the multicentre prospective observational
registry of the German AFNET has been previously de-
scribed in detail [13]. Briefly, 9,574 patients able to give
written informed consent, aged ≥ 18 years and with AF
documented using ECG or Holter-ECG recording—either
at the time of enrolment or within the preceding
12 months—were consecutively enrolled between February
2004 and March 2006 by 191 nationwide study centres
(13 tertiary care cardiology centres, 59 regional hospitals,
63 office-based cardiologists, 36 office-based internists,
and 23 office-based general practitioners). All partici-
pating centres agreed to consecutive enrolment of all eli-
gible AF patients to minimize patient selection bias.
Patients were managed according to local medical
practice. The study was conducted in accordance with the
Helsinki Declaration and approved by the ethics com-
mittee of the Ludwig-Maximilians-University Munich,
Germany (April 19, 2004). Internet-based data collection
via the data capture system MARVIN was hosted by the
Institute for Clinical Cardiovascular Research (Munich,
Germany) as previously described [13]. Current guidelines
on AF management were supplied to investigators during
the initiation visit to provide guidance on state-of-the-art
treatment. Patient follow-up was scheduled for up to
5 years after enrolment. Hospitalised patients (n = 5,068;
52.9 %) as well as outpatients (n = 4,506; 47.1 %) were en-
rolled. Information on prior stroke was available in 9,545
(99.7 %) patients. Medical stroke prevention was assessed
by local investigators immediately before and after the
enrolment visit.
Statistical analysis
Data analysis was performed by the Institut für
Herzinfarktforschung (IHF), Ludwigshafen, Germany
and by the Department of Medical Biometry and
Epidemiology, University Medical Center Hamburg,
Hamburg, Germany. The results were reported as abso-
lute numbers and percentages or mean and standard
deviation. The χ2-test was used to test differences in pro-
portions for dichotomous characteristics and the Mann–
Whitney-Wilcoxon test was applied to detect differences
in the distribution of metric variables. Multivariate statis-
tical analysis was performed at the Department of Medical
Biometry and Epidemiology, University Medical Center
Eppendorf, Hamburg, Germany. In order to cope with
the cluster structure of the data, hierarchal models were
applied with centre identity as a random effect (two-level
random intercept linear mixed models). Two-level linear
mixed models relying on normal assumptions were used
for continuous variables and two-level random effect bino-
mial models were used for binary variables. As a measure
of strength of the cluster effect, intra-class correlations
(ICC, i.e. the proportion of variance between patients at-
tributable to centre differences) were calculated for each
model. In a second step, we introduced centre type as a
fixed four-level factor to the model and determined the
percent reduction of the ICC as a measure of the explana-
tory value of centre type and tested whether the observed
centre type differences were systematic using a likelihood
ratio test of the two models. Subsequently, we examined
the explanatory value of the distinction of inpatient and
outpatient care or of cardiologist and non-cardiologist care
by repeating the analyses with the corresponding two-level
factors. For the binary variable “therapeutic decision for
anticoagulation at discharge”, the model was extended to
incorporate clinical parameters. Two-sided p-values <0.05
were considered significant. Calculations were performed
with SAS, version 9.2, or Stata, version 12.
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Results
Baseline data of registry patients with or without
ischaemic stroke
Overall, 9,545 registry patients were available for this
analysis, 558 (5.8 %) of them reported an ischaemic
stroke, 268 (2.8 %) a transient ischaemic attack (TIA),
and 70 (0.7 %) reported both events prior to enrolment,
resulting in 896 (9.4 %) registry patients with prior is-
chaemic stroke or TIA (“stroke patients”). Of those, 16
(1.8 %) also suffered haemorrhagic stroke prior to enrol-
ment. Baseline characteristics of AF patients with and
without prior ischaemic stroke or TIA are shown in Table 1.
Stroke patients were significantly older (p < 0.0001), more
often female (p < 0.05), and had a higher rate of common
cardiovascular risk factors compared to AF patients
without prior stroke (Table 1). Moreover, AF patients
with prior stroke had permanent AF more frequently
(p < 0.0001) and were less likely to have had a first episode
of AF (p < 0.0001) or paroxysmal AF (p < 0.0001) upon
enrolment (Table 1). The mean CHADS2 [Congestive
heart failure, Hypertension, Age ≥75, Diabetes, Stroke
(doubled)] score among stroke patients was 3.7 ± 1.0.
Secondary stroke prevention prior to enrolment to the
AFNET registry
AF was diagnosed prior to enrolment in 8,507 (89.1 %) of
all study patients while 1,038 (10.9 %) had a first episode
of AF. Excluding stroke patients with oral anticoagulation
contraindications (defined as prior cerebral haemorrhage
(n = 16), major bleeding (n = 37) or known malignancy
(n = 88) and those stroke patients with a first episode of
AF on enrolment (n = 55), and stroke patients with miss-
ing medication information (n = 5)), oral anticoagulation
was deemed guideline-appropriate [14] in 711 (84.5 %) of
841 patients with prior stroke and known AF. Of those
711, 501 (70.5 %) AF patients received anticoagulation
(VKA alone (n = 408), therapeutic dose heparin alone
(n = 26), VKA plus antiplatelet drug(s) (n = 37), and thera-
peutic dose heparin plus antiplatelet drug(s) (n = 30)). In
contrast, 125 (17.6 %) patients received antiplatelet ther-
apy and 85 (12.0 %) no antithrombotic medication. Of
those without antithrombotic medication and known
CHADS2 score, 45 patients (61.6 %) had a CHADS2 ≥ 4.
Compared to 2,570 stroke-free registry patients with a
CHADS2 score of ≥ 2, in whom oral anticoagulation for
primary stroke prevention was indicated according to
guidelines at the time of enrolment [14, 15], stroke pa-
tients were treated significantly more frequently with anti-
coagulants (70.5 % vs. 61.7 %; p < 0.0001) and received no
antithrombotic therapy less frequently (12.0 % vs. 17.8 %;
p < 0.001). In AF patients with prior stroke, as shown in
Fig. 1, only age (OR 0.95 per year; 95 % CI 0.93–0.97) was
inversely associated with anticoagulant therapy before
registry enrolment.
Secondary stroke prevention at the end of the enrolment
visit to the registry
Adequate information regarding medication after enrol-
ment was available for 740 (96.7 %) of the 765 AF patients
with prior stroke and without contraindications for oral
anticoagulation. The majority of stroke patients (76.4 %)
received anticoagulants—usually VKA (95.3 %) or heparin
(therapeutic dose; 4.6 %). Overall, 10.4 % were treated with
VKA or heparin and additional antiplatelets. Furthermore,
118 (15.9 %) patients were treated using antiplatelets and
57 (7.7 %) stroke patients had no medical secondary
stroke prevention. Of those 57 AF patients, 31 (58.5 %)
had a CHADS2 ≥ 4. Compared to 3,062 registry patients
without prior ischaemic stroke and a CHADS2 score
of ≥ 2, stroke patients were treated with anticoagulants
more frequently (76.4 % vs. 69.2 %; p < 0.001; OR 1.44;
95 % CI 1.19–1.73) and were less likely to receive no med-
ical stroke prevention (7.7 % vs. 10.7 %; p < 0.05; OR 0.70;
95 % CI 0.52–0.94).
Table 1 Baseline characteristics of AFNET patients
AF patients without
prior stroke or TIA
n = 8,649
AF patients with





68.1 (11.1) [18–98] 71.3 (9.6) [24–94] <0.0001




First detected 11.4 (983) 6.1 (55) <0.001
Paroxysmal 31.7 (2,737) 26.3 (236) <0.001
Persistent 20.1 (1,739) 21.0 (188) 0.540
Permanent 34.3 (2,967) 43.1 (386) <0.001
Unknown 2.5 (219) 3.5 (31) 0.113
Mitral valve stenosis,
% (n)
2.0 (177) 3.8 (34) <0.001
Valvular replacement,
% (n)
5.1 (440) 5.7 (51) 0.44
Heart failure, % (n) 35.4 (2,877)a 43.7 (370)a <0.0001
Diabetes mellitus,
% (n)
21.1 (1,828) 27.1 (243) <0.0001
Arterial hypertension,
% (n)
68.7 (5,938) 75.8 (679) <0.0001
Coronary artery
disease, % (n)
27.2 (2,120)a 39.0 (309)a <0.0001
Peripheral artery
disease, % (n)
6.5 (537)a 11.0 (93)a <0.0001
Hyperlipidemia, % (n) 45.2 (3,431)a 55.2 (424)a <0.0001
Chronic renal failure,
% (n)
11.0 (907)a 18.7 (159)a <0.0001
an < 8,649 or n < 896, respectively
Baseline characteristics of AF patients with or without prior ischaemic stroke or
TIA on enrolment to the AFNET registry
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According to univariate analysis (Additional file 1:
Table S1), old age, a higher CHADS2 score, chronic
renal failure, and recruitment by a physician working at
a regional hospital or an office-based general practi-
tioner/internist inversely associated with anticoagulant
therapy for secondary stroke prevention after registry
enrolment. After adjustment for confounders and taking
the cluster structure of the data into account (Fig. 1b),
only age (OR 0.95 per year; 95 % CI 0.92–0.97) and the
healthcare provider remained significant factors for oral
anticoagulation prescription. There were no significant
differences in the rates of anticoagulation prescription be-
tween cardiologists working in university hospitals and
office-based cardiologists (OR 1.40; 95 % CI 0.76–2.60),
whereas office-based general practitioners/internists (OR
0.40; 95 % CI 0.21–0.77) or physicians working in regional
hospitals (OR 0.47; 95 % CI 0.29–0.77) prescribed anticoa-
gulation less frequently. As shown in Additional file 2:
Table S2, the largest differences between study centres
were observed across age, AF type, NYHA class, coronary
artery disease, and renal dysfunction. These differences
were only partially explained by centre type (Table 2, 4th
column). Centre differences across AF type, NYHA class,
coronary artery disease, and renal dysfunction could be
sufficiently explained by differences regarding inpatients
and outpatients, but this was not observed for age (Table 2,
7th column and right column). However, the heterogen-
eity of stroke patients treated by different healthcare pro-
viders could not be sufficiently explained by the observed
differences in prescribing anticoagulation for primary or
secondary stroke prevention. For patients with prior
stroke, healthcare providers modestly differed in their
individual anticoagulation prescriptions (intra-class cor-
relation 12.3 %). However, guideline-concordance was
primarily influenced by healthcare provider type (81.4 %
explained). The observed individual healthcare provider
impact was more pronounced in AF patients without
prior stroke (intra-class correlation 18.2 %) whereas
guideline-concordance did not seem to depend on health-
care provider type (12.4 % explained) (Table 2).
Discussion
The AFNET registry provides detailed information regard-
ing overall AF management across a wide variety of
German healthcare modalities [12, 13]. Here, we used the
AFNET registry to identify factors impacting decisions
Fig. 1 Factors associated with prescription of anticoagulants. Factors associated with prescription of anticoagulants before (a) and after (b) enrolment
to the AFNET registry in AF patients with prior ischaemic stroke or TIA
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regarding guideline-based anticoagulant therapy in AF
patients who survived ischaemic stroke. To the best of
our knowledge, comparable information is scarce, be-
cause published data from other AF registries has fo-
cused on stroke prevention in the overall cohort [12].
Moreover, this is one of the first studies to evaluate
systematic, nationwide healthcare differences (including
both hospital and office-based physicians) regarding
stroke prevention in AF patients. Oral anticoagulation
was prescribed after registry enrolment in 69.2 % of all
registry patients considered eligible for anticoagulation
according to the ACC/AHA/ESC 2001 guidelines [13].
This is a much higher rate than the German claims-data
[16], but is similar to that of the Euro Heart Survey (69 %)
and the observational Loire Valley Atrial Fibrillation
Project (66 %) [17]. This may be related to the relatively
high proportion of participating cardiology centres. Tertiary
care cardiovascular centres and office-based cardiologists
recruited approximately two-thirds of all registry patients
[13] and prescribed significantly more anticoagulants than
general practitioners/internists or physicians working in a
regional hospital [12].
This physician-dependent under-utilization of anticoag-
ulants in AF cohorts has been previously described for
office-based general practitioners (versus cardiologists)
[7, 8] but has not yet been extended to a nationwide
healthcare system that includes hospital-based physicians.
The self-reported stroke rate of 9.4 % in the AFNET
registry was similar to those reported in the Euro Heart
Survey on Atrial Fibrillation (10.7 %), or ATRIUM [10],
a prospective German AF registry that focussed on pri-
mary care. Compared to patients without a history of
Table 2 Clinical parameters in 9,545 study patients with prior ischaemic stroke or TIA by type of centre
ICC baseline Univ. hospital vs. Regional hosp. vs.
Cardiologist vs. GP/ Internist
Univ. hospital & Cardiologists vs.




% ex-plained p Residual
ICC [%]
% ex-plained p Residual
ICC [%]
% ex-plained p
Age 25.4 19.6 23.1 <0.0001 19.8 22.2 <0.0001 25.9 0 0.18
Male 0.0002 0.00002 88.9 0.01 0.0001 55.1 0.01 0.00006 74.1 0.07
Atrial fibrillation
First detected 12.5 6.2 50.5 0.17 10.7 14.9 0.16 7.3 41.5 0.07
Paroxysmal 9.6 7.8 18.5 0.001 9.6 0 0.19 7.3 24.0 0.02
Persistent 23.0 13.3 42.0 0.002 21.7 5.55 0.30 23.0 0 0.71
Permanent 20.2 14.4 28.7 0.08 20.3 0 0.89 15.6 22.6 0.03
CHADS2 score 23.0 22.2 3.7 0.047 22.0 4.33 0.01 23.4 0 0.11
Mitral valve stenosis 0.0001 0.0001 0 0.63 0.0001 9.14 0.74 0.0001 0 0.35
Valve replacement 0.0008 0.00004 94.5 0.03 0.0002 72.7 0.39 0.0001 87.4 0.01
Heart failure
None 18.0 18.2 0 0.45 18.4 0 0.48 18.1 0 0.12
NYHA I 42.1 36.4 13.4 0.55 41.9 0.46 0.76 37.9 10.0 0.26
NYHA II 12.0 11.1 7.4 0.62 11.9 0.30 0.83 11.3 6.0 0.34
NYHA III 19.0 12.9 31.8 0.05 18.9 0.32 0.96 14.4 24.2 0.01
NYHA IV 29.0 20.0 31.2 0.003 26.9 7.4 0.14 22.3 23.0 <0.001
Diabetes mellitus 0.0006 0.00008 86.8 0.12 0.0001 77.3 0.03 0.0004 41.0 0.67
Arterial hypertension 9.6 9.5 1 0.62 9.7 0 0.31 9.9 0 0.47
Coronary artery disease 11.7 6 49.2 <0.001 9.9 15.1 0.23 7.1 39.7 0.0001
Peripheral artery disease 10.4 9.2 11.1 0.77 10.3 0.7 0.90 9.4 9.2 0.56
Chronic renal failure 4.3 3 30.7 0.005 4.7 0 0.49 2.8 34.5 <0.001
Patients with prior stroke
Anticoagulation 12.3 2.3 81.4 <0.001 3.5 79.3 <0.001 12.8 0 0.08
Patients without stroke
Anticoagulation 18.2 15.9 12.4 0.003 16.0 12.0 <0.001 17.9 1.41 0.07
Given are baseline intra-class correlations (ICC) as measures of the variability between centres, percent of centre variability explained by centre type or in- vs.
outpatient, respectively, (“% explained”) with corresponding p value, and the residual ICC which could not be explained by the factor under consideration
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stroke prior to enrolment to the AFNET registry, stroke
patients were significantly older, more likely to be fe-
male, and had higher rates of concomitant cardiovas-
cular diseases (Table 1). 70.5 % of AF patients with a
prior history of stroke and without contraindications
for VKAs received anticoagulation before enrolment,
whereas 76.4 % received VKAs following the enrolment
visit. After enrolment, AF patients with a prior history of
stroke received anticoagulation 1.4 times more fre-
quently than stroke-free patients who had a CHADS2
score ≥ 2— i.e. indicative of anticoagulation use for
guideline-adherent primary stroke prevention [14, 15].
Nevertheless, our data clearly indicate that the concomi-
tant cardiovascular risk profile did not have a profound
impact on VKA prescription in stroke patients before or
after enrolment (Additional file 1: Table S1). More spe-
cifically, we found a significantly lower proportion of VKA
use in older stroke patients (OR 0.95 per year; Fig. 1). Un-
like the Euro Heart Survey on Atrial Fibrillation, we did
not find that AF pattern played a role regarding VKA pre-
scription rates in stroke survivors (Fig. 1) [4].
Importantly, we found that several healthcare provider
modalities under-utilized anticoagulants—almost exclu-
sively VKAs. This under-utilization of VKAs was observed
for AF patients with a prior history of stroke, which is
startling, as this patient subset is known to have a very
high risk of recurrent stroke. If university hospital-based
cardiologists were set as a reference, then office-based
cardiologists (OR 1.40) prescribed significantly more
guideline-concordant anticoagulation for secondary stroke
prevention than office-based general practitioners/inter-
nists (OR 0.40) and regional hospitals (OR 0.47) (Fig. 1b).
Though several cardiovascular risk factors varied substan-
tially between centres and centre types (Additional file 2:
Table S2)—largely explained by in- and outpatient differ-
ences—guideline-concordant anticoagulation prescription
for secondary stroke prevention was mainly healthcare
provider dependent. This heterogeneity could not be suffi-
ciently explained by the observed differences between
centre types. Moreover, anticoagulation prescriptions only
modestly differed across individual centres within each
healthcare provider group. The impact of individual
healthcare providers was more pronounced in AF patients
without prior stroke, whereas guideline-concordance
depended less on the type of the treating healthcare pro-
vider in primary stroke prevention (Table 2). In accord-
ance with our results, a recently published sub-analysis of
the retrospective TREAT AF study—based on US health
records and claims data—reported that office-based car-
diologists prescribed significantly more warfarin for AF
patients with a prior history of stroke (OR 1.59; 95 % CI
1.41–1.80) than primary care providers [8]. The results of
the European SAFE-II study [7] are similar but the
total number of stroke patients treated by office-based
cardiologists was lower and an appropriate multilevel
analysis including hospital-based physicians was not
performed.
To both comply with the guidelines and overcome the
suboptimal use of guideline-concordant oral anticoagu-
lants in clinical practice, we recommend improved pa-
tient and physician education. The availability of today’s
non-vitamin K antagonist oral anticoagulants might help
achieve this goal. However, European registry data from
2012 and early 2013 indicate that VKAs are still pre-
dominantly used for AF patient anticoagulation [18, 19].
The strengths of our analysis include the large sample
size of almost 10,000 registry patients with AF, the ability
to discriminate between medical stroke prevention before
and after enrolment to the AFNET registry, the enrolment
in various centre types, as well as the consideration of the
resulting cluster structure in statistical models. However,
our study has several limitations. First, due to the retro-
spective nature of our analysis, we cannot exclude that un-
documented factors have influenced physicians regarding
VKA prescription, and the number of patients refusing to
take VKA is unknown. Second, about 53 % of all registry
patients were enrolled during an in-hospital stay. There-
fore, secondary stroke prevention at hospital discharge
might have been affected by diagnostic or therapeutic pro-
cedures carried out or planned in-hospital. Third, willing-
ness to participate in the registry might inadvertently
select patients and centres, as suggested by the high rate
of anticoagulant use at enrolment into the AFNET regis-
try. Therefore, we cannot comprehensively assess the im-
plementation of antithrombotic medication for stroke
prevention in AF patients in the general German popula-
tion. Fourth, all registry patients were enrolled before the
non-vitamin K antagonist oral anticoagulants became
available.
Conclusions
Medical secondary stroke prevention was in accordance
with applicable guidelines in more than three quarters of
all registry patients with prior ischaemic stroke or TIA
after enrolment to the AFNET registry. Nevertheless, sec-
ondary stroke prevention was not sufficiently tailored to
individual stroke risk profiles. As reported for unselected
AF patients in the AFNET registry, guideline-concordant
use of anticoagulants in stroke patients with AF depended
on the type of the treating health-care provider, indicating
an under-utilization of anticoagulants among general
practitioners/internists and physicians working in regional
hospitals. Counterintuitively, guideline-concordance in pa-
tients with a prior history of stroke—a group of patients at
high risk of recurrent stroke -depended even more on the
type of the treating health-care provider. Therefore, our
data suggest that increased use of specialist care can im-
prove stroke prevention in AF patients.
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Additional file 1: Table S1. Guideline adherence in patients with
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Additional file 2: Table S2. Baseline characteristics according to type
of enrolling centre.
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